

Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer

NCT04624399

Status	RECRUITING
Phase	Phase 2
Sponsor	Queen Mary University of London
Enrollment	58 participants

Key Eligibility Criteria

Inclusion (30)

- UTUC cohort:
- Histopathologically confirmed, high grade or high risk upper urinary tract urothelial carcinoma (renal pelvis and ureter). This cohort includes all patients with upper tract malignancy who in the opinion of the investigators qualify for radical surgery (nephroureterectomy or distal ureter resection). Urothelial carcinoma of the upper urinary tract qualifies as high-risk disease if any of the below factors are present:
- Hydronephrosis
- Tumour size ≥ 2 cm on cross sectional imaging
- High grade cytology
- ... and 25 more (see full listing online)

Exclusion (25)

- Pregnant and lactating female patients.
- Major surgical procedure within 4 weeks prior to enrolment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis.
- Previously intravenous chemotherapy for urothelial cancer.
- Patients with prior allogeneic stem cell or solid organ transplantation.
- Prior treatment with CD137 agonists, anti-CTLA-4, anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents.
- ... and 20 more (see full listing online)

Locations (1 total)

Barts and London Hospital NHS Trust, London, United Kingdom